Published online Nov 7, 2015. doi: 10.3748/wjg.v21.i41.11767
Peer-review started: April 21, 2015
First decision: May 18, 2015
Revised: June 20, 2015
Accepted: August 31, 2015
Article in press: August 31, 2015
Published online: November 7, 2015
Colorectal cancer (CRC) is a common malignancy worldwide. In CRC patients, metastases are the main cause of cancer-related mortality. In a group of metastatic CRC patients, the metastases are limited to a single site (solitary organ); the liver and lungs are the most commonly involved sites. When metastatic disease is limited to the liver and/or lungs, the resectability of the metastatic lesions will dictate the management approach and the outcome. Less commonly, the site of solitary organ CRC metastasis is the peritoneum. In these patients, cytoreduction followed by hyperthermic intraperitoneal chemotherapy may improve the outcome. Rarely, CRC involves other organs, such as the brain, bone, adrenals and spleen, as the only site of metastatic disease. There are limited data to guide clinical practice in these cases. Here, we have reviewed the disease characteristics, management approaches and prognosis based on the metastatic disease site in patients with CRC with metastases to a single organ.
Core tip: Colorectal cancer (CRC) is a common malignancy. In CRC patients, metastases are the main cause of cancer-related mortality. Cancer spread can sometimes be limited to a single organ, representing a malignancy with a distinct biological profile and clinical characteristics. In CRC patients with single site metastases, the resectability of the metastases and the site of metastatic disease affect the clinical characteristics, the optimal management approach and the prognosis.